Back to Search Start Over

Periodontal tissue regeneration using fibroblast growth factor-2: randomized controlled phase II clinical trial

Authors :
Hidetoshi Shimauchi
Keisuke Nakashima
Toshihide Noguchi
Jun-ichi Kido
Yuichi Izumi
Takao Hirofuji
Masami Ninomiya
Enyu Imai
Takafumi Hamachi
Takashi Sasano
Katsumasa Maeda
Yukio Iwayama
Shogo Takashiba
Toshihiko Nagata
Yoshitaka Hara
Takeo Fujii
Masahiro Kitamura
Shinya Murakami
Toshi Furuuchi
Mitsuru Watanuki
Hidemi Kurihara
Mitsuo Fukuda
Yusuke Kowashi
Masatoshi Omae
Toshiaki Shibutani
Source :
PLoS ONE, PLoS ONE, Vol 3, Iss 7, p e2611 (2008)
Publication Year :
2007

Abstract

Background: The options for medical use of signaling molecules as stimulators of tissue regeneration are currently limited. Preclinical evidence suggests that fibroblast growth factor (FGF)-2 can promote periodontal regeneration. This study aimed to clarify the activity of FGF-2 in stimulating regeneration of periodontal tissue lost by periodontitis and to evaluate the safety of such stimulation. Methodology/Principal Findings: We used recombinant human FGF-2 with 3% hydroxypropylcellulose (HPC) as vehicle and conducted a randomized double-blinded controlled trial involving 13 facilities. Subjects comprised 74 patients displaying a 2- or 3-walled vertical bone defect as measured ?3 mm apical to the bone crest. Patients were randomly assigned to 4 groups: Group P, given HPC with no FGF-2; Group L, given HPC containing 0.03% FGF-2; Group M, given HPC cotaining 0.1% FGF-2; and Group H, given HPC Containing 0.3% FGF-2. Each patient underwent flap operation during which we administered 200 μL of the appropriate investigational drug to the bone defect. Before and for 36 weeks following administration, patients underwent periodontal tissue inspections and standardized radiography of the region under investigation. As a result, a significant difference (p = 0.021) in rate of increase in alveolar bone height was identified between Group P (23.92%) and Group H (58.62%) at 36 weeks. The linear increase in alveolar bone height at 36 weeks in Group P and H was 0.95 mm and 1.85 mm, respectively (p = 0.132). No serious adverse events attribute to the investigational drug were identified. Conclusions: Although no statistically significant differences were noted for gains in clinical attachment level and alveolar bone gain for FGF-2 groups versus Group P, the significant difference in rate of increase in alveolar bone height (p = 0.021) between Groups P and H at 36 weeks suggests that some efficacy could be expected from FGF-2 in stimulating regeneration of periodontal tissue in patients with periodontitis.<br />PLoS ONE, 3(7), e2611; 2008

Details

ISSN :
19326203
Volume :
3
Issue :
7
Database :
OpenAIRE
Journal :
PloS one
Accession number :
edsair.doi.dedup.....ecdf0e1aa597e6dedd8c68e302a5b8f8